Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-928

Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inogapendekin alfa is recombinant human IL-15 with an amino acid substitution (Asn72Asp/N72D) that enhances its agonist activity at the IL-15Rβγc complex. IL-15N72D increases biological activity by 4-5-fold compared to the wild type cytokine. Inogapendekin alfa enhance the immunity and inhibit viral infections.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-928-1mg 1mg 3090
GMP-Bios-INN-928-10mg 10mg Inquiry
GMP-Bios-INN-928-100mg 100mg Inquiry
GMP-Bios-INN-928-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215
INN Name Nogapendekin Alfa
TargetIL15RA
FormatRecombinant Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeIL15 (interleukin 15, IL-15) variant N72>D
VD LCIL15 (interleukin 15, IL-15) variant N72>D
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesAltor BioScience (FL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0